The risk of grade 3 AEs and higher hypertension and proteinuria were greater in patients treated with the EGFR-TKIs plus bevacizumab combination (Supplementary Tables S1 and S2; Supplementary Figure S3A–E). This evidence concerns the gene EGFR and Hypertension.